UNSPSC 51293613: Iprindole hydrochloride

This classification denotes a tricyclic antidepressant C19H28N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z023VDR216, chemically known as 6,7,8,9,10,11-hexahydro-n,n-dimethyl-5h-cyclooct)(b)indole-5-propanamine, hydrochloride, but more generally known as iprindole hydrochloride, which bears US NIH Compound Identifier 159889. European Medicines Agency schedules Iprindole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02768MIG.

Most nations, for tariff and trade purposes, schedule iprindole hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, IPRINDOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2C3C1CCCCCC3.CL.

UNSPSC 51293613 Iprindole hydrochloride is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code show minimal alignment with the iprindole compound itself. Instead, the code appears in procurement activity spanning broader pharmaceutical and health-supply acquisition — including naloxone distribution, direct-to-manufacturer prescription programs, and multi-source generic drug supply agreements. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The actual buying activity reflects operational health-system procurement for emergency medications, pharmacy benefit program restructuring, and bulk generic pharmaceutical supply through authorized wholesaler networks rather than procurement specific to iprindole hydrochloride.

Activity is concentrated in Florida and Texas, with broader multistate participation through MMCAP's cooperative vehicle serving Oregon and other member jurisdictions. Representative solicitations include Seminole County's IFB60459723LAS (issued June 2026, due July 26, 2026) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (issued April 2026) exploring direct-to-manufacturer prescription program capabilities; and MMCAP's RFP S1070000015802 (issued January 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including Cencora and Cardinal Health. The code shows recent activity but does not reflect focused procurement of iprindole hydrochloride itself — vendors pursuing this code should verify whether a specific opportunity's actual scope aligns with their product or service line before investing in response.